Capabilities by Region: Continental Europe
Greenhill has considerable advisory experience in Continental Europe. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout Continental Europe. Greenhill established its presence in Continental Europe in November 2000 with the opening of a Frankfurt office. Greenhill further expanded its presence with the opening of a Madrid office in 2017 and a Paris office in 2020.
For more information on Greenhill’s advisory practice in Continental Europe and our capabilities in the region, please contact President David Wyles in our London office, Managing Director Philip Meyer Horn in our Frankfurt office, Javier Gonzalez in our Madrid Office or Amélie Négrier-Oyarzabal in our Paris office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
EYSA
Advising Tikehau Capital, global mid-market fund headquartered in France, in the acquisition of EYSA, a leading provider of smart mobility solutions, focusing on both urban and interurban mobility services for municipalities, transport authorities and infrastructure owners
German Doner Kebab ("GDK")
Advised Hero Brands on the strategic investment in GDK by True. GDK is a leading Middle Eastern quick-service restaurant brand, with over 145 franchised locations in the UK and 170 globally, including the US, Canada, Sweden and the Middle East
Renewi plc
Advising Renewi plc, a leading European waste-to-product company, on its £707 million recommended cash offer for its entire issued share capital from a consortium controlled by Macquarie Asset Management and British Columbia Infrastructure Management Corporation (BCI)
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
Robertet SA
Advising Fonds Stratégique de Participations and Peugeot Invest SA, on the acquisition of a 14% stake for €250 million in Robertet SA, world leader in natural products, from DSM-Firmenich AG